Overview
Retatrutide is an investigational medication candidate developed by Eli Lilly. It is a triple agonist, meaning it targets three hormone receptors: GLP-1, GIP and glucagon. Researchers are studying how these pathways may affect appetite, food intake, energy expenditure and metabolic health.
How it works
Research is evaluating how simultaneous activity at GLP-1, GIP and glucagon receptors may influence appetite, glucose metabolism and energy balance.
GLP-1
A pathway involved in appetite, food intake and glucose regulation.
GIP
A hormone pathway being studied for its role in metabolic signalling.
Glucagon
A pathway involved in energy balance and glucose metabolism.
Current research
Clinical studies are evaluating efficacy, safety and tolerability in different populations. Findings should be interpreted in the context of each trial's design, population, dose and duration.
Potential benefits
Research has reported weight-loss and metabolic outcomes in clinical studies. These findings describe study populations and do not guarantee an individual outcome.
Limitations
Trial results cannot by themselves establish that an investigational medicine is appropriate or safe for a particular person. Regulatory status and evidence can also change as research develops.
Key takeaways
- Retatrutide is an investigational triple agonist.
- It is being evaluated across clinical-development programmes.
- Research findings need to be interpreted study by study.
- It is not approved for general public use.